ATE469220T1 - ANTIBODIES THAT MODIFY CANCER DISEASES - Google Patents

ANTIBODIES THAT MODIFY CANCER DISEASES

Info

Publication number
ATE469220T1
ATE469220T1 AT05714544T AT05714544T ATE469220T1 AT E469220 T1 ATE469220 T1 AT E469220T1 AT 05714544 T AT05714544 T AT 05714544T AT 05714544 T AT05714544 T AT 05714544T AT E469220 T1 ATE469220 T1 AT E469220T1
Authority
AT
Austria
Prior art keywords
antibodies
cancer
cancer diseases
modify cancer
modify
Prior art date
Application number
AT05714544T
Other languages
German (de)
Inventor
David Young
Susan Hahn
Lisa Cechetto
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE469220T1 publication Critical patent/ATE469220T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, and hematogenous cells.
AT05714544T 2004-02-26 2005-02-28 ANTIBODIES THAT MODIFY CANCER DISEASES ATE469220T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54866704P 2004-02-26 2004-02-26
PCT/CA2005/000302 WO2005083064A1 (en) 2004-02-26 2005-02-28 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
ATE469220T1 true ATE469220T1 (en) 2010-06-15

Family

ID=34911008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05714544T ATE469220T1 (en) 2004-02-26 2005-02-28 ANTIBODIES THAT MODIFY CANCER DISEASES

Country Status (15)

Country Link
US (1) US7399835B2 (en)
EP (1) EP1718737B1 (en)
JP (1) JP2008504227A (en)
CN (1) CN1934246A (en)
AT (1) ATE469220T1 (en)
AU (1) AU2005217008A1 (en)
CA (1) CA2557093A1 (en)
DE (1) DE602005021459D1 (en)
DK (1) DK1718737T3 (en)
ES (1) ES2345260T3 (en)
NZ (1) NZ549409A (en)
PL (1) PL1718737T3 (en)
PT (1) PT1718737E (en)
SI (1) SI1718737T1 (en)
WO (1) WO2005083064A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080025977A1 (en) * 2003-04-14 2008-01-31 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20060140963A1 (en) * 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US20080213169A1 (en) * 2003-04-14 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59
US7452979B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7494648B2 (en) * 2005-08-02 2009-02-24 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
US7456259B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7456258B2 (en) * 2005-08-02 2008-11-25 Arius Research, Inc. Cancerous disease modifying antibodies
US7452978B2 (en) * 2005-08-02 2008-11-18 Arius Research, Inc. Cancerous disease modifying antibodies
US7411046B2 (en) * 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
RU2009122233A (en) * 2006-11-13 2010-12-20 Ф.Хоффманн-Ля Рош Аг (Ch) ANTIBODIES MODIFIING CANCER DISEASES
CN101668849A (en) * 2007-03-26 2010-03-10 霍夫曼-拉罗奇有限公司 Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3
EP2178918A1 (en) * 2007-07-16 2010-04-28 F.Hoffmann-La Roche Ag An anti-cancer cytotoxic monoclonal antibody
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
US9605074B2 (en) * 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4433059A (en) * 1981-09-08 1984-02-21 Ortho Diagnostic Systems Inc. Double antibody conjugate
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
NZ222509A (en) 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5171665A (en) 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
DE69229254T2 (en) 1991-10-30 1999-09-23 Idemitsu Kosan Co Processes for the production of human lymphocytes and human antibodies; and antibodies so produced
IL105008A0 (en) 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
JPH10505819A (en) 1994-06-24 1998-06-09 ヴラディミール ピー． トーチリン Use of autoantibodies for treatment and prevention of tumors
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
WO2003024191A2 (en) * 2001-09-21 2003-03-27 Raven Biotechnologies, Inc. Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
WO2003030831A2 (en) 2001-10-11 2003-04-17 Protein Design Labs, Inc. Treatment of prostate cancer by inhibitors of atp synthase
AU2003227148A1 (en) 2002-04-05 2003-10-27 Arius Research, Inc. Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
US20060140963A1 (en) 2003-04-14 2006-06-29 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of CD59

Also Published As

Publication number Publication date
WO2005083064A1 (en) 2005-09-09
US7399835B2 (en) 2008-07-15
EP1718737A1 (en) 2006-11-08
CA2557093A1 (en) 2005-09-09
AU2005217008A1 (en) 2005-09-09
ES2345260T3 (en) 2010-09-20
JP2008504227A (en) 2008-02-14
NZ549409A (en) 2009-12-24
PT1718737E (en) 2010-08-09
CN1934246A (en) 2007-03-21
SI1718737T1 (en) 2010-09-30
EP1718737B1 (en) 2010-05-26
PL1718737T3 (en) 2010-10-29
EP1718737A4 (en) 2007-03-28
DK1718737T3 (en) 2010-08-09
US20050191305A1 (en) 2005-09-01
DE602005021459D1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
ATE469220T1 (en) ANTIBODIES THAT MODIFY CANCER DISEASES
WO2007095749A8 (en) Cytotoxicity mediation of cells evidencing surface expression of trop-2
CY1106455T1 (en) CANCER MODIFYING ANTIBODIES
MX2009007619A (en) Cancerous disease modifying antibodies.
WO2004065422A3 (en) Cancerous disease modifying antibodies
BRPI0601736A (en) adjuvant therapy methods, nonmetastatic breast cancer cure method, disease recurrence reduction method, instruction method of human patients with non-metastatic her2-positive breast cancer, production method and commercial methods
MX2009001015A (en) Cancerous disease modifying antibodies.
MX2009007617A (en) Cancerous disease modifying antibodies.
MX2009007618A (en) Cancerous disease modifying antibodies.
WO2005012361A3 (en) Antibodies raised against colon carcinomas
WO2003086456A3 (en) Anti-ck18 monoclonal antibody and therapeutic and diagnostic uses thereof in cancer
BR0309226A (en) Methods for producing a vascular damaging effect in a warm-blooded animal, and for treating cancer involving a solid tumor in a warm-blooded animal, pharmaceutical composition, kit, and uses of zd6126 or salt thereof pharmaceutically acceptable salt and zd1839 or a pharmaceutically acceptable salt thereof
ATE483028T1 (en) ANTIBODIES THAT MODIFY CANCER DISEASES
DE60331827D1 (en) COMPOSITIONS FOR THE RADIOIMMUN THERAPY OF BRAIN TUMORS
MX2009011667A (en) Cancerous disease modifying antibodies.
MX2009009919A (en) Cancer disease modifying antibody 010207-01 produced by hybridoma cell line ar51a630.3.
MX2009001292A (en) Cancerous disease modifying antibodies.
DK1360208T3 (en) Method for Preparation of Cytotoxic Anticancer Antibodies
WO2008058380A8 (en) Cancerous disease modifying antibodies
AR070279A1 (en) CANCEROSE DISEASE MODIFYING ANTIBODIES (CDMA)
NO20091459L (en) Cancerous disease-modifying antibodies
BRPI0718609A8 (en) CANCER DISEASE MODIFYING ANTIBODIES.
AR072750A1 (en) CANCEROSE DISEASE MODIFYING ANTIBODIES
AR071847A1 (en) MONOCLONAL ANTIBODIES MODIFYING CANCER DISEASES
AR070278A1 (en) INSULATION AND PRODUCTION OF CANCER DISEASE MODIFYING ANTIBODIES (CDMAB) AND USE OF THE SAME

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1718737

Country of ref document: EP